Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bahn

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Diabetes Care|November 10, 2010
Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes TrialRobert J Anderson, Gideon D Bahn, Thomas E Moritz, et al.
Diabetes Care|September 25, 2019
Intensive Glycemic Control Improves Long-term Renal Outcomes in Type 2 Diabetes in the Veterans Affairs Diabetes Trial (VADT)Lily Agrawal, Nasrin Azad, Gideon D Bahn, et al.
Diabetes Care|October 9, 2013
Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT)Nasrin Azad, Lily Agrawal, Nicholas V Emanuele, et al.
Diabetes Care|July 22, 2011
Observation on renal outcomes in the Veterans Affairs Diabetes TrialLily Agrawal, Nasrin Azad, Nicholas V Emanuele, et al.
Diabetes Care|March 24, 2016
Association of Blood Glucose Control and Lipids With Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT)Nasrin Azad, Gideon D Bahn, Nicholas V Emanuele, et al.
Diabetologia|November 5, 2017
Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)Lily Agrawal, Nasrin Azad, Gideon D Bahn, et al.
American Journal of Preventive Cardiology|May 27, 2024
Haptoglobin phenotype and intensive glycemic control for coronary artery disease risk reduction in people with type two diabetes: The Veterans Affairs Diabetes TrialLeah E Cahill, Rachel A Warren, Gideon D Bahn, et al.
The New England Journal of Medicine|June 6, 2019
Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-upPeter D Reaven, Nicholas V Emanuele, Wyndy L Wiitala, et al.
Clinical Therapeutics|February 4, 2014
Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteersSamuel S Dychter, Rena Harrigan, Jesse D Bahn, et al.
The New England Journal of Medicine|June 4, 2015
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetesRodney A Hayward, Peter D Reaven, Wyndy L Wiitala, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Diabetes Care|November 10, 2010
Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes TrialRobert J Anderson, Gideon D Bahn, Thomas E Moritz, et al.
Diabetes Care|September 25, 2019
Intensive Glycemic Control Improves Long-term Renal Outcomes in Type 2 Diabetes in the Veterans Affairs Diabetes Trial (VADT)Lily Agrawal, Nasrin Azad, Gideon D Bahn, et al.
Diabetes Care|October 9, 2013
Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT)Nasrin Azad, Lily Agrawal, Nicholas V Emanuele, et al.
Diabetes Care|July 22, 2011
Observation on renal outcomes in the Veterans Affairs Diabetes TrialLily Agrawal, Nasrin Azad, Nicholas V Emanuele, et al.
Diabetes Care|March 24, 2016
Association of Blood Glucose Control and Lipids With Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT)Nasrin Azad, Gideon D Bahn, Nicholas V Emanuele, et al.
Diabetologia|November 5, 2017
Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT)Lily Agrawal, Nasrin Azad, Gideon D Bahn, et al.
American Journal of Preventive Cardiology|May 27, 2024
Haptoglobin phenotype and intensive glycemic control for coronary artery disease risk reduction in people with type two diabetes: The Veterans Affairs Diabetes TrialLeah E Cahill, Rachel A Warren, Gideon D Bahn, et al.
The New England Journal of Medicine|June 6, 2019
Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-upPeter D Reaven, Nicholas V Emanuele, Wyndy L Wiitala, et al.
Clinical Therapeutics|February 4, 2014
Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteersSamuel S Dychter, Rena Harrigan, Jesse D Bahn, et al.
The New England Journal of Medicine|June 4, 2015
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetesRodney A Hayward, Peter D Reaven, Wyndy L Wiitala, et al.
Pageof 2